Arcus Biosciences' kidney cancer drug shows breakthrough trial results
Arcus Biosciences has bolstered its financial position, securing funds to operate through 2028. The influx comes as its drug casdatifan demonstrates promising results in treating late-stage kidney cancer. Early data hint that it may outperform existing treatments in certain patient groups.
The company now seeks to hasten development, with key trials already underway and more data anticipated soon.
Casdatifan, a HIF-2α inhibitor, has exhibited encouraging results in late-line renal cell carcinoma (RCC). In a Phase 1/2 study, it achieved a 45% objective response rate (ORR) and a median progression-free survival (PFS) of 15.1 months. These figures surpass belzutafan, an approved rival drug, which reported a 25% ORR and 14.9 months PFS in similar patients.
The drug's performance has led Arcus to advance it into Phase 3 trials. The CONTAINER study, initiated in 2024, focuses on clear cell RCC, particularly in patients with VHL mutations. Meanwhile, belzutafan—developed by Merck and Peloton—has shown effectiveness in VHL-altered tumours but with slightly lower response rates.
Arcus views RCC as a significant commercial opportunity, estimating its potential value in the billions. The company plans to expand casdatifan's use into first-line treatments, potentially reducing dependence on tyrosine kinase inhibitors (TKIs). To expedite approval, the PEAK-1 Phase 3 trial is underway, with regulatory submissions expected in the coming years.
Beyond casdatifan, Arcus is preparing to move two immunology programs into clinical testing. Mature data from combination therapy studies will also be released soon, adding to the company's pipeline momentum.
With extended funding and strong trial results, Arcus Biosciences is propelling casdatifan toward regulatory approval. The drug's performance in late-stage kidney cancer positions it as a potential leader in a competitive market. Further data and trial outcomes will determine its broader use in earlier treatment lines.
